[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 6, 1956

ANDROGEN THERAPY

Author Affiliations

Endocrine Clinic, Department of Medicine University of California School of Medicine San Francisco 22.

JAMA. 1956;162(6):600. doi:10.1001/jama.1956.02970230072021

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

To the Editor:—  In the last 20 years the introduction of potent testosterone compounds has for the first time made it possible to induce androgenic effects in patients suffering from male hypogonadism. Soon after the successful synthesis of testosterone, it was found that certain esters, notably the propionate, produce greater androgenic activity, and testosterone propionate became the most popular agent for androgen substitution therapy. This compound is a potent androgen but is not ideal for human therapeutic use because it is only effective when given by frequent intramuscular injections, e.g., 25 mg. three times a week. Methyltestosterone is more convenient because it is effective when swallowed, but only in doses four or more times as large as those of testosterone propionate, rendering it an expensive form of therapy. At the endocrine clinic, University of California School of Medicine, sublingually administered methyltestosterone has been practically as effective as injected testosterone propionate,

First Page Preview View Large
First page PDF preview
First page PDF preview
×